Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-12062026-273373
EXTRAORDINARY
PART II—Section 3—Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 2906]
NEW DELHI, THURSDAY, JUNE 11, 2026/JYAISTHA 21, 1948
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICALS PRICING AUTHORITY)
ORDER
New Delhi, the 11th June, 2026
S.O. 3004(E). - Whereas the National Pharmaceutical Pricing Authority (NPPA) was established vide the
Resolution of the Government of India in the Ministry of Chemicals and Fertilizers No. 33/7/97-PI.I dated 29th August,
1997, inter-alia, to fix prices and notify the changes therein, if any, of bulk drugs and formulations, monitor the prices
of non-scheduled drugs and formulations and oversee the implementation of the provisions of the Drugs (Price Control)
Order (DPCO);
2.
And whereas, the Ministry of Chemicals and Fertilizers vide S.O.1394 (E) dated the 30th May, 2013, in
exercise of the powers conferred by Section 3 and 5 of Essential Commodities Act, 1955 has delegated the powers in
respect of specified paragraphs of the DPCO, 2013, including paragraph 19 of the said Order to be exercised by the
NPPA on behalf of the Central Government;
3.
And whereas, NPPA has been receiving applications for upward price revision under paragraph 19 of DPCO,
2013 citing various reasons like increase in cost of Active Pharmaceutical Ingredients, increase in cost of production,
exchange rates etc. resulting in unviability in sustainable production and marketing of the drugs;
4.
And whereas, in 2019, Committee on Affordable Medicines and Health Products (CAMHP, earlier known as
SCAMHP), NITI Aayog, Government of India provided guidance on the modalities/ methodology to be followed.
CAMHP in its 2nd meeting held on 07.11.2019 recommended an increase of 50% in the ceiling prices and also
authorized NPPA to examine additional formulations / molecules experiencing similar issues of manufacturing
unviability due to low prices and apply upward price revision on principles determined by CAMHP;
5.
And whereas, the Authority, based on the said guidance, has previously allowed one-time upward revision of
ceiling prices for certain essential scheduled formulations in public interest to ensure their continued availability in the
market;
6.
And whereas, NPPA examined applications relating to Carboplatin 10 mg/ml Injection and Cisplatin 1 mg/ml
Injection based on data and information available with NPPA and submissions made by applicant companies, including
information relating to trends in API prices during the period 2021-2022 to 2025-2026;
7.
And whereas, the Committee constituted by the Authority for examination of cases under paragraph 19 of the
Drugs (Prices Control) Order, 2013, in its 8th meeting held on 18.05.2026 considered the applications and recommended
that Carboplatin 10 mg/ml Injection and Cisplatin 1 mg/ml Injection may be considered for an appropriate upward price
revision;
8.
And whereas, the Authority noted concerns regarding shortage and supply disruptions of Carboplatin and
Cisplatin formulations, which are essential oncology medicines used in the treatment of various cancers, as highlighted
by healthcare institutions, oncologists, manufacturers and other stakeholders;
9. And whereas, the Authority further noted that the prices of Carboplatin API and Cisplatin API have reportedly
increased substantially during recent years, adversely impacting the viability of production and supply of these
formulations;
10.
And whereas, the Authority observed that uninterrupted availability of Carboplatin and Cisplatin formulations
is critical for public health and patient care and that non-availability of such formulations may lead to disruption of
treatment and compel patients to shift to costlier alternatives, wherever available;
11. And whereas, the Authority, after deliberating upon the recommendations of the Committee constituted under
paragraph 19 of the Drugs (Prices Control) Order, 2013, the reported shortages, increase in API and other input costs,
and the need to ensure continued availability of these critical oncology medicines, invoked the extraordinary powers in
public interest under paragraph 19 of the said Order for upward revision of the ceiling prices of the said formulations by
allowing a one-time increase of 50% over the prevailing ceiling prices; and further decided that, in view of the wide
fluctuations in raw material prices, the revised ceiling prices shall be reviewed after six months, or earlier, as warranted;
12.
Now, therefore, in exercise of extra ordinary powers in public interest, conferred by paragraph 19 of the Drugs
(Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India
in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the
Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in
column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the
prices as specified in column (5) of the Table below as ceiling prices exclusive of Goods and Services Tax applicable,
if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with
the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
+-----+-----------------------------------+------------------------+----------+---------------------------------+-------------------------+----------------+
| Sl. | Name of the | Dosage form & Strength | Unit | Approved revised Ceiling Price | Existing S.O. No. | Date |
| No. | Scheduled Formulation | | | (Rs.) | | |
+=====+===================================+========================+==========+=================================+=========================+================+
| (1) | (2) | (3) | (4) | (5) | 6(a) | 6(b) |
+-----+-----------------------------------+------------------------+----------+---------------------------------+-------------------------+----------------+
| 1. | Carboplatin | Injection 10 mg/ml | Per ML | 90.74 | 1575(E) Sl. No. 141 | 25.03.2026 |
+-----+-----------------------------------+------------------------+----------+---------------------------------+-------------------------+----------------+
| 2. | Cisplatin | Injection 1 mg/ml | Per ML | 10.89 | 1575(E) Sl. No. 182 | 25.03.2026 |
+-----+-----------------------------------+------------------------+----------+---------------------------------+-------------------------+----------------+
Note:
(a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified
by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified
in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(b) The provisions of paragraph 13(2) of DPCO 2013 would not be applicable on the ceiling price specified in column (5)
in respect of the formulations with dosage & strength mentioned in column (2) and (3) respectively.
(c) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government
on the ceiling price mentioned in column (5) of the above said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph
11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug
Controller and dealers.
(e) As per paragraph 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if
any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so
as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table
launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall apply for prior price
approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production
/ import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any
manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the
NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of
the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the
overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with
Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification,
the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.
[PN/279/147/2026/F/ F. No. 8(147)/2026/DP/Div-II/NPPA]
BHIVA RAM YADAV, Assistant Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.
Login to read full text